On October 26, 2023 Evaxion Biotech A/S (NASDAQ: EVAX) ("Evaxion" or the "Company"), a clinical-stage TechBio company specializing in developing AI-Immunology-powered vaccines, reported that it will be presenting clinical readouts on its two personalized cancer vaccine trials at SITC (Free SITC Whitepaper)’s 38th annual meeting, taking place in San Diego, California from November 1-5, 2023 (Press release, Evaxion Biotech, OCT 26, 2023, View Source [SID1234636370]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
The results will be presented in two posters:
1. Title: "AI-designed personalized neoantigen vaccine, EVX-02, induces robust T-cell responses in melanoma patients"
Poster #: 623
Location: Exhibit Hall B – San Diego Convention Center
Time: Friday, November 3, 9 a.m. – 7 p.m. PDT
This poster will be presented by Evaxion’s senior project manager, Daniela Kleine-Kohlbrecher. The abstract was also selected by the SITC (Free SITC Whitepaper) Communications Committee to be presented at the SITC (Free SITC Whitepaper) 2023 Annual Meeting Press Conference, scheduled for Wednesday, November 1, from 12:00–1:30 p.m. PDT.
2. Title: "Effects of an AI-generated personalized neopeptide-based immunotherapy, EVX-01, in combination with pembrolizumab in patients with metastatic melanoma. A clinical trial update"
Poster #: 782-H
Location: Exhibit Hall B – San Diego Convention Center
Time: Saturday, November 4, 9 a.m. – 8:30 p.m. PDT
This poster will be presented by principal investigator Professor Adnan Khattak from the Hollywood Private Hospital in Nedlands, Australia.
Christian Kanstrup, Chief Executive Officer at Evaxion, commented, "We are thrilled about the continuous buildup of positive clinical evidence for the unique predictive capabilities of our AI-immunology platform, which we believe holds promise for truly groundbreaking cancer treatments."
Birgitte Rønø, Chief Scientific Officer at Evaxion, expressed her enthusiasm about the upcoming conference, stating, "We are looking forward to sharing these promising clinical trial results with the SITC (Free SITC Whitepaper) community, showcasing the advantages of our AI-Immunology platform to design personalized cancer vaccines. We believe this takes us one step closer to bringing novel treatments to the market and meeting the pressing global medical need for cancer patients."
About EVX-01 Phase 2 Clinical Trial
EVX-01 is Evaxion’s lead clinical asset and constitutes a peptide-based personalized cancer vaccine. The Phase 2 clinical study is a self-sponsored open-label, single-arm, multi-center trial carried out in collaboration with Merck Sharp & Dohme LLC, together with leading principal investigators and research centers from Italy and Australia, and aims at evaluating the efficacy and safety of EVX-01 vaccination in combination with anti-PD1 treatment (pembrolizumab) in treatment-naive patients with metastatic or unresectable malignant stage III or IV melanoma. More information can be accessed under clinical trial ID NCT05309421.
About EVX-02 Phase 1/2a Clinical Trial
The EVX-02 Phase 1/2a represents Evaxion’s first-in-human DNA-based personalized cancer vaccine study. This open-label, multi-center study aims at assessing the safety, tolerability, pharmacodynamic responses, and efficacy of EVX-02 neoantigen vaccine and anti-PD-1 treatment (nivolumab) in patients who have had a complete resection of a Stage IIIB/IIIC/IIID or Stage IV melanoma with risk of recurrence. More information can be accessed under clinical trial ID NCT04455503.